Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
GLP-1s are biologic-style peptide drugs that require specialized manufacturing
Across the ten emerging indications examined, obstructive sleep apnea was the most common co-occurring diagnosis, present in 25.5% of GLP-1 patients between 2018 and 2024, followed by major depressive disorder at 18.2%, CKD at 10.6% and NAFLD/NASH at 10.3% (Figure 2)
Studies demonstrate the peptide prevents NSAID-induced gastric ulcers and accelerates healing of existing ulcerations (Sikiric et al., Journal of Physiology and Pharmacology, 2017)
bioRxiv2026 Jan 23
US$ 24.45
US$ 21.36
US$ 28.56
US$ 24.79
US$ 22.31
US$ 28.55
US$ 23.18
US$ 28.86
US$ 22.27
